Cell Cycle and Related Protein

by John Farley, Laurent Ozbun, Goli Samimi, Michael J. Birrer
Published 2007-01-01

Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer

by Brandon M. Roane, Rebecca C. Arend, Michael J. Birrer
Published 2019-05-01

p21-activated kinase 3 (PAK3) is an AP-1 regulated gene contributing to actin organisation and migration of transformed fibroblasts.

by Nina Holderness Parker, Howard Donninger, Michael J Birrer, Virna D Leaner
Published 2013-01-01

Biomarkers of Mucinous Tumors of the Ovary

by Goli Samimi, Laurent Ozbun, Michael E. Johnson, Samuel C. Mok, Michael J. Birrer
Published 2007-01-01

Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.

by Vinod Vathipadiekal, Deepa Saxena, Samuel C Mok, Peter V Hauschka, Laurent Ozbun, Michael J Birrer
Published 2012-01-01

Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer

by Ru-pin Alicia Chi, Pauline van der Watt, Wei Wei, Michael J. Birrer, Virna D. Leaner
Published 2021-02-01

An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer.

by Geetika Sethi, Harsh B Pathak, Hong Zhang, Yan Zhou, Margret B Einarson, Vinod Vathipadiekal, Sumedha Gunewardena, Michael J Birrer, Andrew K Godwin
Published 2012-01-01

Inflammatory Cytokine Tumor Necrosis Factor α Confers Precancerous Phenotype in an Organoid Model of Normal Human Ovarian Surface Epithelial Cells

by Joseph Kwong, Franky Leung Chan, Kwong-kwok Wong, Michael J. Birrer, Kyra M. Archibald, Frances R. Balkwill, Ross S. Berkowitz, Samuel C. Mok
Published 2009-06-01

Etiology and Pathogenesis of Epithelial Ovarian Cancer

by Samuel C. Mok, Joseph Kwong, William R. Welch, Goli Samimi, Laurent Ozbun, Tomas Bonome, Michael J. Birrer, Ross S. Berkowitz, Kwong-Kwok Wong
Published 2007-01-01

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

by Elizabeth K. Lee, Zhenying Tan-Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Horowitz, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Joyce F. Liu
Published 2019-08-01

CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.

by Amanda Sosulski, Heiko Horn, Lihua Zhang, Caroline Coletti, Vinod Vathipadiekal, Cesar M Castro, Michael J Birrer, Osamu Nagano, Hideyuki Saya, Kasper Lage, Patricia K Donahoe, David Pépin
Published 2016-01-01

ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression

by Tsz-Lun Yeung, Ching Chou Tsai, Cecilia S. Leung, Chi-Lam Au Yeung, Melissa S. Thompson, Karen H. Lu, Ralph S. Freedman, Michael J. Birrer, Kwong-Kwok Wong, Samuel C. Mok
Published 2018-11-01

Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor κB Pathway and Is Associated with Poor Overall Survival

by Adam Clauss, Vivian Ng, Joyce Liu, Huiying Piao, Moises Russo, Natalie Vena, Qing Sheng, Michelle S. Hirsch, Tomas Bonome, Ursula Matulonis, Azra H. Ligon, Michael J. Birrer, Ronny Drapkin
Published 2010-02-01

Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer

by Dong Choon Park, Seung Geun Yeo, Mark R. Wilson, Justin J. Yerbury, Joseph Kwong, William R. Welch, Yang Kyu Choi, Michael J. Birrer, Samuel C. Mok, Kwong-Kwok Wong
Published 2008-09-01

Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutation...

by Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Roisin O'Cearbhaill, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael J. Birrer
Published 2020-08-01

SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment

by Ying Zhu, Sammy Ferri-Borgogno, Jianting Sheng, Tsz-Lun Yeung, Jared K. Burks, Paola Cappello, Amir A. Jazaeri, Jae-Hoon Kim, Gwan Hee Han, Michael J. Birrer, Samuel C. Mok, Stephen T. C. Wong
Published 2021-04-01

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncolo...

by Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael Frumovitz, Samir N. Khleif, Warner K. Huh, Michael J. Birrer
Published 2020-02-01

Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment

by Whitney N. Goldsberry, Selene Meza-Perez, Angelina I. Londoño, Ashwini A. Katre, Bryan T. Mott, Brandon M. Roane, Nidhi Goel, Jaclyn A. Wall, Sara J. Cooper, Lyse A. Norian, Troy D. Randall, Michael J. Birrer, Rebecca C. Arend
Published 2020-03-01

Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

by Ruogu Qi, Yongheng Wang, Peter M. Bruno, Haihua Xiao, Yingjie Yu, Ting Li, Sam Lauffer, Wei Wei, Qixian Chen, Xiang Kang, Haiqin Song, Xi Yang, Xing Huang, Alexandre Detappe, Ursula Matulonis, David Pepin, Michael T. Hemann, Michael J. Birrer, P. Peter Ghoroghchian
Published 2020-04-01

Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

by Ruogu Qi, Yongheng Wang, Peter M. Bruno, Haihua Xiao, Yingjie Yu, Ting Li, Sam Lauffer, Wei Wei, Qixian Chen, Xiang Kang, Haiqin Song, Xi Yang, Xing Huang, Alexandre Detappe, Ursula Matulonis, David Pepin, Michael T. Hemann, Michael J. Birrer, P. Peter Ghoroghchian
Published 2018-02-01